

Freya Biosciences named as one of Fierce Biotech's "Fierce 15" for 2026

- *Recognition reflects Freya's scientific progress and commitment to addressing significant unmet needs in women's health*

Copenhagen, Denmark and Boston, Massachusetts, 5 October 2026: Freya Biosciences ("Freya" or "the Company"), a clinical-stage immunology company developing therapies to treat inflammation and immune dysregulation in women, today announces that Fierce Biotech, a division of Forge, has named it as one of 2026's Fierce 15 biotechnology companies, designating it as one of the most innovative and promising private biotechnology companies in the industry.

Freya is advancing novel immunology-based therapies targeting the underlying drivers of disease in conditions that affect women. The recognition follows a year of significant progress for the Company, including positive Phase 1 results for its lead candidate, FB301, a potential treatment for IVF-related embryo implantation failure. The first-in-human study met all primary and secondary endpoints, demonstrating that FB301 was safe and well tolerated across all cohorts, with no serious or severe adverse events or treatment discontinuations reported.

Colleen Acosta, Chief Executive Officer of Freya Biosciences, commented: *"We are honored to have been named one of Fierce Biotech's "Fierce 15". This achievement is a testament to the dedication, expertise and passion of our team, as well as the potential of our approach to addressing significant unmet needs in women's health. With positive Phase 1 results for FB301 marking an important milestone this year, we look forward to building on this progress as we advance our pipeline and work towards delivering transformative therapies for women."*

Ayla Ellison, Editor-in-Chief, Fierce Life Sciences and Healthcare, said: *"For 24 years, the Fierce 15 has highlighted private biotechs doing some of the most interesting and ambitious work in the industry. This year's class arrives at a moment when momentum is returning to biotech, with more capital flowing and new opportunities opening up for promising companies. These 15 biotechs stand out for the strength of their science and the potential of their approaches to shape the next generation of medicines."*

The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. This is Fierce Biotech's 24th annual Fierce 15 selection.

Every year Fierce Biotech evaluates hundreds of early-stage companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

- ENDS -

For further information, please contact:

Optimum Strategic Communications

Mary Clark, Isabelle Abdou, Katie Flint, Aoife Minihan

Tel: +44 (0) 203 922 0889

Email: freya@optimumcomms.com

About Freya Biosciences



Freya Biosciences is a clinical-stage immunology company developing therapies treating inflammation and immune dysregulation in conditions that affect women. Freya is advancing a diversified pipeline, including two first-in-class Phase 2-ready assets for IVF-related embryo implantation failure and preterm birth.

Freya's science is powered by its Dyscover™ platform, a unique multi-omics data science platform built on a biobank of 1,000+ patient samples, including intervention data at scale. This provides deep insights into disease pathway associated markers, allowing for de-risked target identification and patient stratification.

Backed by a world-class team with a proven track record in biologics drug development, and supported by an international investor base, including Sofinnova Partners, the Gates Foundation, OMX Ventures, EIFO, and Angelini Ventures, Freya is addressing a critical gap in women's health, developing disease-modifying therapies for patients with conditions where current treatments fall short. For more information, visit our [website](#) and follow Freya on [LinkedIn](#).

About Fierce Biotech

Fierce Biotech covers the biopharma waterfront, from drug development through the entire lifecycle – tracking regulatory approvals, payer negotiations, manufacturing, marketing, patent fights, government investigations and regulation, M&A deals and beyond. Our aim is to analyze the day's news, showing readers not only what they need to know, but why they need to know it. Beyond the daily, the Fierce Biotech team produces special reports that take stock of the industry's products and finances and shed new light on industry trends.

www.fiercebiotech.com

About Forge

Forge is a leading global B2B events and media company, connecting buyers and sellers across high-value industries through live events, trusted media brands, digital products and year-round communities. Powered by first-party data, technology and deep market expertise, Forge helps businesses discover opportunities, build the right relationships and stay engaged well beyond the event itself. It is a company guided by a single purpose, Moving Markets.

For more information, visit forgelive.com.